NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Enters Common Stock Purchase Agreement with Lincoln Park Capital
INmune Bio (NASDAQ: INMB) this morning announced a common stock purchase agreement with Chicago-based institutional investor Lincoln Park Capital Fund, LLC (“LPC”) for up to $20 million, including an initial investment of $300,000. The investment amount is subject to the terms of the agreements with Lincoln Park and is in addition to LPC’s investment during the first round of funding in 2017, when INmune was a private company. Subject to compliance with the transaction documents, INmune will have the option to sell up to an additional $19.7 million in shares to LPC over a 24-month period. INmune believes this funding…







